INC Research receives best Service Variability Index score, a measure of consistency in meeting customer expectations, that far exceeds the industry average

Raleigh, NC, Feb. 29, 2012 - INC Research, LLC, a therapeutically focused clinical research organization (CRO) with a Trusted Process^® for delivering reliable results, today announced the Company has received the "most consistent service quality ratings of all the companies profiled" in the 2012 CRO Quality Benchmarking Report published by Industry Standard Research (ISR). For the 2012 study, ISR interviewed 125 individuals from 72 pharmaceutical and biotechnology companies to provide insight into Phase II/III clinical development outsourcing trends as well as assessments of CROs.

 "INC Research prides itself on building strong relationships with its customers and consistently delivering the highest quality clinical development services on their behalf," said Jim Ogle, Chief Executive Officer. "This focus is the essence of the Trusted Process^®, our proprietary, metrics-driven clinical outsourcing methodology specifically designed to reduce variability while maintaining a high standard of quality and remaining flexible to meet our customers' complex and changing needs." He continued, "The results of this survey further demonstrate that when you choose INC Research as your clinical development partner you can expect your project to start quickly and efficiently, your milestones to be met and your team to be comprised of the best professionals in our industry."

The 2012 CRO Quality Benchmarking Report provides performance scorecards on 25 CROs, with CROs being scored across 21 critically important service capabilities that affect provider selection and deliver quality. Key highlights of INC Research's performance:

• INC Research received the best score on the Service Variability Index (SVI), a measure of consistency in meeting customer expectations. The lower the score, the less variability of the service provider from "ideal."  INC Research received a score of 14, substantially better than the industry average of 25. 
• INC Research scored better than the industry average for "Service Provider Loyalty," "Overall Satisfaction with Service Providers," "Willingness to Recommend Service Providers" and "Likelihood to Use Service Providers Again." 
• ISR recommends INC Research be shortlisted by companies who value Operational Independence (turning studies over to experts who work independently). 
• INC Research received high marks for its global footprint and was recommended to be shortlisted by companies planning global trials.  

"In a year in which they completed a large acquisition, INC Research shows a very solid performance profile," adds Kevin Olson, Chief Executive Officer, Industry Standard Research. "The Company received the most consistent quality ratings of all of the companies we profiled, and their customers are very satisfied."

About ISR

Industry Standard Research is the premier, full-service market research provider to the pharma and pharma services industries.  With more than a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.  For more information, visit the ISR website at www.ISRreports.com or email info@ISRreports.com. The company also may be found on Twitter @ISRreports.

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs  in all therapeutic areas and innovative pediatric and women's health trials. The Company's Trusted Process^® methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.

CONTACT: Lori Dorer, Media, (513) 345-1685